Compare FPI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | MNPR |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 587.4M |
| IPO Year | 2013 | 2019 |
| Metric | FPI | MNPR |
|---|---|---|
| Price | $9.71 | $107.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | N/A | ★ $107.00 |
| AVG Volume (30 Days) | ★ 385.2K | 213.9K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $52,178,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $962.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.37 | $29.18 |
| 52 Week High | $13.23 | $116.64 |
| Indicator | FPI | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 61.46 |
| Support Level | $9.45 | $52.92 |
| Resistance Level | $9.92 | $112.57 |
| Average True Range (ATR) | 0.16 | 8.45 |
| MACD | 0.03 | -1.06 |
| Stochastic Oscillator | 55.87 | 53.84 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.